Phosphatidyglycerol Incorporates into Cardiolipin to Improve Mitochondrial Activity and Inhibits Inflammation

Wei-Wei Chen1, Yu-Jen Chao1, Wan-Hsin Chang1, Jui-Fen Chan1 & Yuan-Hao Howard Hsu1,2

Chronic inflammation and concomitant oxidative stress can induce mitochondrial dysfunction due to cardiolipin (CL) abnormalities in the mitochondrial inner membrane. To examine the responses of mitochondria to inflammation, macrophage-like RAW264.7 cells were activated by Kdo2-Lipid A (KLA) in our inflammation model, and then the mitochondrial CL profile, mitochondrial activity, and the mRNA expression of CL metabolism-related genes were examined. The results demonstrated that KLA activation caused CL desaturation and the partial loss of mitochondrial activity. KLA activation also induced the gene upregulation of cyclooxygenase (COX)-2 and phospholipid scramblase 3, and the gene downregulation of COX-1, lipooxygenase 5, and Δ-6 desaturase. We further examined the phosphatidyglycerol (PG) inhibition effects on inflammation. PG supplementation resulted in a 358-fold inhibition of COX-2 mRNA expression. PG(18:1)2 and PG(18:2)2 were incorporated into CLs to considerably alter the CL profile. The decreased CL and increased monolysocardiolipin (MLCL) quantity resulted in a reduced CL/MLCL ratio. KLA-activated macrophages responded differentially to PG(18:1)2 and PG(18:2)2 supplementation. Specifically, PG(18:1)2 induced less changes in the CL/MLCL ratio than did PG(18:2)2, which resulted in a 50% reduction in the CL/MLCL ratio. However, both PG types rescued 20–30% of the mitochondrial activity that had been affected by KLA activation.

External infections induce the activation of toll-like receptors (TLRs) or nucleotide-binding oligomerization domain-like receptors (NLRs) to trigger inflammation1. Multiple enzyme types, such as phospholipases and cyclooxygenases (COXs), can be activated in macrophages to produce proinflammatory prostaglandins, followed by conversion to anti-inflammatory lipoxins2. Some studies have suggested that unresolved antigens may induce autoimmune disease and chronic inflammation3,4; in turn, chronic inflammation and concomitant oxidative stress damage mitochondrial DNA and functions, which promote aging2.

Mitochondria are the main source of mitochondrial reactive oxygen species (mtROS) production, which activate NLRP3 to produce proinflammatory factors6. Macrophage activation repurposes the mitochondria from adenosine triphosphate (ATP) synthesis to ROS production7, but mitochondrial defects can further increase oxidative stress and promote inflammation8. Mitophagy is a selective pathway to prevent mtROS accumulation and excessive inflammation6. The promotion of cellular respiration of blood vessels during the macrophage-mediated engulfment of steroids increases oxidative stress, which leads to cardiolipin (CL) oxidation and mitochondrial defects8,9. The reduction of oxidative stress in the mitochondria alleviates atherosclerosis and chronic inflammation10.

CLs are negatively charged phospholipids that are specifically localized on the mitochondria and account for 15–20% of mitochondrial lipids. Because of their unique structure with four acyl chains, CLs are responsible for the curvature formation of the mitochondrial inner membrane11. In addition, CLs are critical in the stabilization of protein complexes on the mitochondrial inner membrane, such as electron transfer chain (ETC) I, III, and IV, as well as ATP synthase (which ensures ETC efficiency)12. CLs are prone to oxidation because of their location in the mitochondria, leading to reduced ATP production13,14. A lack of CL remodeling and excessive CL oxidation reduces CL symmetry, which can be crucial in certain mammalian organs15,16. Oxidized CLs can reduce...
their affinity toward cytochrome c, and result in cytochrome c release into the cytosol and subsequent apoptotic pathway activation.\textsuperscript{19-23}

CL synthase combines phosphatidylglycerol (PG) and cytidine diphosphate diacylglycerol (CDP-DAG) to synthesize CLs in eukaryotic mitochondria. These nascent CLs are further remodeled with the acyl chains from phosphatidylcholine or phosphatidylethanolamine to produce mature CLs through tafazzin (TAZ).\textsuperscript{24} CL remodeling alters the CL profile depending on the availability of fatty acyl chains in the environment, which can be manipulated by nutrient deprivation and lipid supplementation.\textsuperscript{25,26} TAZ gene mutations on the X chromosome also cause mitochondrial abnormalities in patients with Barth syndrome.\textsuperscript{27} Phospholipase (PL) A\textsubscript{2} is a CL remodeling and degradation enzyme that can hydrolyze fatty acyl chains to form monolysocardiolipins (MLCLs) or dilyso-CLs.\textsuperscript{28} According to our review of the relevant literature, eicosanoid production has never been reported to be associated with CL degradation in the mitochondria.

PG was discovered in Scenedesmus and contains a glycerol backbone-linked glycerol headgroup and two fatty acyl chains.\textsuperscript{29} PG is distributed in the animal cell mitochondria as a precursor for CL synthesis,\textsuperscript{30} and when located in lung surfactant, is critical for innate immunity regulation.\textsuperscript{31-33} PG competes with lipopolysaccharides to disrupt the activation of the TLR pathway, thus inhibiting the formation of downstream inflammatory molecules.\textsuperscript{34,35} However, PG-induced anti-inflammatory properties in the mitochondria have not been thoroughly studied. Therefore, we supplemented RAW264.7 cells with PG(18:1) and PG(18:2) to evaluate the effects of PG on CL synthesis and remodeling, mitochondrial functions, and the mRNA expression of CL metabolism-related genes after Kdo2-Lipid A (KLA)-induced macrophage activation.

Results

Mass spectrometry analysis of CLs and MLCLs in RAW264.7 cells. To quantify the concentration of CLs, MLCLs, and DLCLs in a complex biological sample, we established a liquid chromatography–mass spectrometry (MS) detection method. CL(14:0) was partially hydrolyzed by secretory PLA\textsubscript{2} to produce the monolysophosphatidylglycerol (MLCL) and dilyso-CL, and then analyzed by a mass spectrometer with a reverse phase chromatography. The mass spectrum of (A) CL, (B) MLCL, (C) DLCL, and the chromatography of (D) CL, (E) MLCL, (F) DLCL are shown.

![Figure 1.](image-url)

**Figure 1.** The mass spectrum and chromatography of CL, MLCL and DLCL. The CL(14:0) was hydrolyzed by secretory PLA\textsubscript{2} to produce the monolysophosphatidylglycerol (MLCL) and dilyso-CL, and then analyzed by a mass spectrometer with a reverse phase chromatography. The mass spectrum of (A) CL, (B) MLCL, (C) DLCL, and the chromatography of (D) CL, (E) MLCL, (F) DLCL are shown.
Acyl hydrolysis increased the polarity of CL metabolites; therefore, MLCL and DLCL traveled faster in the C18 column.

CLs and MLCLs are major phospholipids of the inner mitochondrial membrane. To access the integrity of the mitochondrial membrane structure, we identified and quantified the concentration of CLs and MLCLs in RAW264.7 cells, but DLCL was too scarce to be detected. The chromatographic analysis of CLs and MLCLs in the lipid extract from RAW264.7 cells demonstrated delayed retention times compared with that of the internal CL standard (Fig. 2A); longer chain length of the extracted CLs were determined to attribute to this delay. In addition, the hydrolysis of one fatty acyl chain on CL to form MLCL slightly shifted the retention time due to increased polarity. The species of CLs and MLCLs with the same acyl chain length were categorized in groups (Fig. 2B,C). CLs had six major groups (CL64, CL66, CL68, CL70, CL72, and CL74) and MLCLs were divided in four major groups (MLCL50, MLCL52, MLCL54, and MLCL56). In addition, each group comprised 4–6 species with various double bonds. To accurately identify the fatty acyl chains in CLs and MLCLs, tandem MS was performed for phospholipid fragmentation (Fig. 2D,E). Because phosphoester bonds on phosphates and ester bonds on fatty acids are weak covalent bonds that can be easily broken, phosphatidic acid and fatty acids were the common product ions on the MS/MS spectrum.

We identified CL and MLCL species in RAW264.7 cell by LC-MS/MS. Based on the structure of CL and its charge, total lipid extraction is analyzed by reverse phase chromatography and mass spectrometry in negative mode. The methodology for CL analysis and identification are described in previous studies from our laboratory25,26. In our measurement, Raw 264.7 cell contains 55 CL species with 42 types of molecular weights, and each species are identified and shown in Table 1. For MLCL analysis, the signal of extracted ion chromatogram of MLCL standard (C14:0) appeared by around 24 min. The retention time of MLCL in samples, which contain more long-chain MLCL, was eluted around 26–30 min. The results showed that MLCL species shows five clusters in m/z range of 1100–1300 and 33 MLCL species with 16 molecular weights (Table 2). The identification of MLCL was carried out by secondary fragmentation. As an example, in MLCL species (C18:1), the fragments are 435, 699, and 835 m/z, which contains one acyl chain plus a phosphate group, two acyl chains plus a phosphate group, and two acyl chains with a glycerol backbone and two phosphate groups.

**Incorporation of PG(18:1)2 into CLs and phospholipids.** CLs are biologically synthesized from PG and CDP-DAG by CL synthase in the mitochondria of mammalian cells. We attempted to manipulate the CL
Table 1. CL identification in Raw 264.7 cell.

| Species | m/z  | Formula | Species | m/z  | Formula |
|---------|------|---------|---------|------|---------|
| C56:0   | 1239.7 | (14:0)(14:0)(14:0) | C72:8   | 1447.8 | (18:2)(18:2)(18:2)(18:2)(18:2)(18:2) |
| C64:2   | 1347.9 | (16:0)(16:0)(16:1) | C72:9   | 1446.3 | (16:1)(18:1)(22:6)(16:1) |
| C64:3   | 1345.9 | (18:1)(16:1)(14:0)(16:1) | C74:6   | 1480.1 | (20:3)(18:1)(18:1)(18:1) |
| C64:4   | 1344.8 | (16:1)(16:1)(16:1) | C74:7   | 1477.8 | (18:2)(20:3)(18:1)*(18:1)(18:1)(18:3)(18:2) |
| C66:1   | 1377.8 | (16:0)(18:0)(16:1)(16:0) | C74:8   | 1473.8 | (18:1)(16:1)(20:3)(18:1)*(18:1)(18:1)(18:3)(18:2) |
| C66:2   | 1375.9 | (16:0)(18:1)(16:0)(16:1) | C74:9   | 1470.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C66:3   | 1373.9 | (16:0)(16:1)(16:0)(18:2) | C75:6   | 1480.1 | (20:3)(18:1)(18:1)(18:3)(18:2)(18:2) |
| C66:4   | 1371.9 | (18:1)(16:1)(16:1)(16:1) | C76:0   | 1477.8 | (18:1)(16:1)(20:3)(18:1)*(18:1)(18:1)(18:3)(18:2) |
| C66:5   | 1370.7 | (16:1)(16:1)(16:1)(18:2) | C76:1   | 1474.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C68:2   | 1403.8 | (16:0)(18:1)(16:0)(18:1) | C76:2   | 1471.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C68:3   | 1402.0 | (16:1)(18:1)(18:1)(16:0) | C76:3   | 1469.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C68:4   | 1399.9 | (16:1)(18:1)(16:1)(18:1) | C76:4   | 1467.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C68:5   | 1397.8 | (16:1)(18:2)(18:1)(16:1) | C76:5   | 1465.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C68:6   | 1395.7 | (18:2)(16:1)(18:2)(16:1) | C76:6   | 1463.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C70:2   | 1423.2 | (18:1)(18:0)(18:1)(16:0) | C76:7   | 1460.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |
| C70:3   | 1425.8 | (18:1)(18:1)(18:0)(18:1) | C76:8   | 1458.8 | (18:1)(16:1)(20:3)(18:2)(18:1) |

*Bold: identified species
*Main species

Table 2. MLCL identification in RAW264.7 cell.

| Species | m/z  | Formula | Species | m/z  | Formula |
|---------|------|---------|---------|------|---------|
| C50:3   | 1135.80 | (34:2)(16:1)(32:0)(18:1) | C56:7   | 1211.81 | (36:3)(20:4)(38:6)(18:1)(38:4)(18:3) |
| C50:2   | 1137.73 | (16:0)(16:1)(18:1)(34:2)(16:0) | C56:6   | 1213.63 | (36:2)(20:4)(38:5)(18:1)(38:6)(18:1) |
| C52:3   | 1164.11 | (34:2)(18:1)(36:2)(16:1) | C56:5   | 1215.83 | (38:4)(18:1)(36:1)(20:4) |
| C52:2   | 1165.98 | (34:1)(18:1)(36:2)(16:0) | C56:4   | 1217.83 | (38:3)(18:1)(38:4)(18:0) |
| C53:4   | 1170.95 | (36:2)(17:2)(36:3)(17:1)(35:3)(18:1) | C56:3   | 1219.81 | (36:2)(17:1)(36:2)(18:1) |
| C53:3   | 1176.48 | (35:2)(18:2) | C58:8   | 1238.01 | (40:8)(18:0)(40:7)(18:1)(36:2)(22:6) |
| C53:2   | 1177.12 | (36:2)(17:1)(35:2)(18:1) | C58:5   | 1241.67 | (36:2)(22:4)(40:6)(18:0)(36:1)(22:5)(40:4)(18:2) |
| C54:5   | 1187.78 | (36:4)(18:1)(36:3)(18:2)(34:1)(20:4) | C58:4   | 1243.67 | (36:2)(22:4)(40:6)(18:0)(36:1)(22:5)(40:4)(18:2) |
| C54:4   | 1189.78 | (36:3)(18:1)(36:2)(18:2)(34:1)(20:3) | C58:3   | 1245.67 | (36:2)(22:4)(40:6)(18:0)(36:1)(22:5)(40:4)(18:2) |
| C54:3   | 1191.62 | (36:2)(18:1)(36:3)(18:0) | Bold: identified species. *Main species a: predicted formula |
CL increased drastically, and the diversity of the CL groups decreased. After the second supplementation, only three major CL groups were detected (CL70, CL72, and CL74), with CL72 being predominant. Notably, the mass peak in CL72 at m/z 1455.4 was for the symmetrical CL(18:1)4, which indicates the incorporation of the 18:1 fatty acyl chain into CLs. After the second supplementation, CL(18:1)4 was the most abundant CL species in RAW264.7 cells, which suggests the efficient incorporation of the 18:1 fatty acyl chain from PG to CL in the first and second supplementation. PG(18:1)2 supplementation remarkably increased the percentage of symmetrical CLs. Furthermore, we evaluated the effects of PG(18:1)2 supplementation in fresh media to RAW264.7 cells during cell passage (Supplemental Fig. S2). Although the initial supplementation significantly altered the CL profile, the effects were minimal, despite the 8-day maintenance of the experiments. Therefore, these results reveal that two-time PG supplementation is the optimal supplementation method for CL remodeling; it was the standard protocol used in the following experiments for the present study.

We further examined the two-time PG supplementation effects on phosphatidylglycerol (PG), phosphatidylcholine (PC) and phosphatidylethanolamine (PE) (Fig. 4). After PG(18:1)2 supplementation, the concentration of PG(18:1)2 in mitochondria increased 9.6 folds, indicating the supplemented PG(18:1)2 successfully entering mitochondria. The concentrations of PC(18:1)2 and PS(18:1)2 increases 2.4 folds and 1.4 folds respectively. These

Figure 3. The mass spectrum of the CL in RAW264.7 after PG(18:1)2 supplementation. (A) The CL pattern of RAW264.7 was analyzed by LC-MS. RAW264.7 cells are further supplemented with 1 to 4 times of 50μM PG in a 12-hour interval. The addition was at time (B) 0, (C) 12, (D) 24, (E) 36 hours. All cells were harvested at 48 hours.

Figure 4. Mitochondrial phospholipid changes upon PG supplementation. RAW264.7 cells were supplemented with 50μM of PG(18:1)2 twice. Mitochondria were purified and the phospholipids were then extracted by Bligh-Dyer’s method. The PG, PC and PS in the sample were analyzed by LC-MS/MS. Minor species, a: (16:1)(16:0), b: (16:1)(18:1) and c: (18:0)(18:2) were also detected with the dominant species. The experiments were performed in triplicate and statistically analyzed by t-test (**p < 0.01, ***p < 0.001).
results indicated that the imported PG(18:1) 2 in mitochondria stimulated either the conversions among PG, PC and PE phospholipids or the remodeling of PC and PE in mitochondria.

**PG(18:1) 2 supplementation produces a higher percentage of symmetrical CLs than does PG(18:2) 2 supplementation.** CLs are mainly composed of 18:1 and 18:2 fatty acyl chains in animal cells. CL symmetry is also critical for CL maturation [17]. As indicated in the preceding section, we supplemented RAW264.7 cells with 50 μM of PG(18:1) 2 and PG(18:2) 2 twice to alter CL compositions (Fig. 5). PG(18:1) 2 supplementation increased the dominant CL chain length to CL72. Specifically, CL(72:3) and CL(72:4) increased from 1.4% to 12.1% and from 3.6% to 28.1%, respectively, which were the species with the highest increase percentage. By contrast, CL66 and CL68 were the groups with decreasing percentages, most evident within CL(66:4) and CL(68:4) (3.6% and 9.56% decrease, respectively). Additionally, CL70, C72, and C74 showed a significant reduction in CL saturation.

Following PG(18:2) 2 supplementation, the shift of CL68 and CL70 to CL72 and CL74, respectively, was significant. In addition to the increase in chain length, CL saturation decreased drastically. The species with more than four double bonds increased in percentage, which strongly indicates the incorporation of the 18:2 fatty acyl chain to replace the fatty acids with 0–1 double bonds. CL(72:6), CL(72:7), and CL(72:8) in CL72, and CL(74:6), CL(74:7), and CL(74:9) in CL74 showed a significant increase in percentage. Conversely, CL(68:4) decreased by 10.2%, which is the most remodeled species.

In short, the CL70, CL72, and CL74 groups showed a high variation in CL species after PG(18:1) 2 and PG(18:2) 2 supplementation. PG(18:1) 2 supplementation produced CLs with 2–4 double bonds, and PG(18:2) 2 supplementation produced CLs with 5–8 double bonds. We also confirmed that the PG(18:1) 2 and PG(18:2) 2 supplementation increases the abundance of 18:1 and 18:2 fatty acyl chain in CL respectively.

MLCLs are considered to be the hydrolyzed products of CLs because the biological synthesis of MLCLs has yet to be reported; nevertheless, it is suspected that the species and concentrations of MLCLs are strongly related to those of CLs. In the present study, we examined the changes in MLCLs after PG supplementation (Fig. 6). After the addition of PG(18:1) 2, MLCL(54:3) increased drastically from 10.16% to 34.84% to become the major MLCL species. In addition, MLCL(54:6) showed a significant percentage increase of 6.6%. However, the percentages of the short chain MLCL50 and MLCL52 species decreased. PG(18:2) 2 supplementation resulted in a significant increase of 10.6%, 8.2%, 4.3%, and 8.3% in MLCL(54:5), MLCL(54:6), MLCL(56:5), and MLCL(56:6), respectively. PG(18:1) 2 supplementation specifically increased the percentage of MLCL(18:1) 2, which is different from the effects of PG(18:2) 2 supplementation that increased the percentage of multiple unsaturated species. These effects on MLCLs are in accordance with those on CLs, supporting the conceptualization that MLCLs are the hydrolysis products of CLs.

However, a 50-μM CDP-DAG supplementation of RAW264.7 cells resulted in nonsignificant changes in both CLs and MLCLs (Supplemental Fig. S3), suggesting that CDP-DAG may be unable to incorporate into CL through external supplementation.

**Effects of PG supplementation and KLA activation on CLs and MLCLs.** In the RAW264.7 inflammation model, KLA-induced TLR4 activation altered the phospholipid composition and CL saturation [36]. PG suppresses inflammation [37], and in the present study, PG supplementation drastically changed CL compositions in RAW264.7 cells (Fig. 3); therefore, the mechanisms through which PG suppresses inflammation and affects CL compositions during macrophage activation are worth exploring. We supplemented KLA (TLR-4-specific agonist)-activated cells with PG and analyzed the quantity of CLs and MLCLs and the CL/MLCL ratio (Fig. 7).

The CL and MLCL quantity in RAW264.7 cells were 1.50 and 0.06 fmole/cell, respectively, with a CL/MLCL ratio.

![Figure 5. Analysis of the percentages of CL species in RAW264.7 cells after PG supplementation. RAW264.7 cells were supplemented with 50 μM of (A) PG(18:1) 2 and (B) PG(18:2) 2 twice at time 0 and 12 hours. The cells were harvested at 48 hours. The 28 CL species were analyzed by IonTrap mass spectrometry.](image-url)
After KLA activation for 24 hours, the quantity of CLs and MLCLs per cell did not change significantly. After PG(18:1) supplementation for 48 hours, the CL quantity decreased to 0.75 fmole/cell, which reduced the CL/MLCL ratio to 10.8. After both PG(18:1) supplementation and KLA activation, the CL quantity was 1.29 fmole/cell, and the MLCL quantity was 0.14 fmole/cell. Therefore, the CL/MLCL ratio did not fluctuate and was maintained at 9.5.

After PG(18:2) supplementation for 48 hours, the CL and MLCL quantities were 1.02 and 0.11 fmole/cell, respectively, with a CL/MLCL ratio of 9.4. This is similar to the quantity changes that occurred after PG(18:1) supplementation. However, KLA activation of PG(18:2)-supplemented cells resulted in a drastic decrease in the CL/MLCL ratio to 5.4. Although supplementation with both PG types decreased the CL concentration and increased the MLCL concentration, PG(18:2)-supplemented cells tended to increase the MLCL percentage of the total CL species after KLA activation, indicating that CL(18:2) is an unfavorable CL species after KLA activation.

KLA triggered differential changes in the CL composition of PG-supplemented RAW264.7 cells (Fig. 8A). After the KLA activation of cells without PG supplementation, the CL species with increased percentages were as follows: CL(66:2), 1.12%; CL(68:1), 1.22%; CL(68:2), 3.40%; and CL(70:2), 1.46%. All of these species had less than two double bonds. By contrast, the CL species with decreased percentages had more than four double bonds.

Figure 6. PG supplementation effects on MLCL in RAW264.7. RAW264.7 cells were supplemented with 50 μM of (A) PG(18:1) and (B) PG(18:2) at time 0 and 12 hours. The cells were harvested at 48 hours. There were 12 MLCL species analyzed by IonTrap mass spectrometry.

Figure 7. CL and MLCL changes in RAW264.7 upon PG supplementation and KLA activation. The RAW264.7 cells were primed with PG for 24 hours and then treated with KLA for another 24 hours before harvest. The quantity of CL and MLCL is based on the sum of the MS XIC of CL or MLCL to internal standard. The numbers above the bars are the value of CL/MLCL.
bonds and are listed as follows: CL(66:4), 1.65%; CL(68:4), 3.54%; CL(70:4), 1.43%; and CL(70:7), 1.03%. Because the CL species has been identified, we were able to examine the KLA effects on the saturation of CL. Upon KLA treatment, the esterified fatty acid 16:1 on CL (16:1)(18:1)/(16:1)(18:1) were saturated to 16:0 on CL (16:0)(18:1)/(16:0)(18:1) to increase the overall CL saturation. When cells were pretreated with PG(18:1)2 to alter CL compositions and subsequently activated by KLA (Fig. 8B), most of the CL species did not change except CL(72:4), and the symmetrical CL(18:1)4 remained the most abundant CL species. When cells were pretreated with less saturated PG(18:2)2 and KLA (Fig. 8C), CL saturation did not change drastically, except a slight 1.38% decrease in CL(72:7). The percentage of symmetrical CL(18:2)4 was expected to increase after PG(18:2)2 supplementation; however, it decreased.

PG supplementation rescues mitochondrial activity in RAW264.7 cells after KLA activation.

After PG supplementation and KLA treatment, the mitochondrial activity in RAW264.7 cells was examined using a Seahorse XF-24 extracellular flux analyzer (Fig. 9). The overall oxygen consumption rates (OCRs) decreased after KLA activation in the absence of PG (Fig. 9A). Specifically, the OCRs from basal respiration, ATP production, and maximal respiration were significantly reduced by 46%, 35%, and 67%, respectively.

Without KLA activation, PG(18:1)2-supplemented cells did not exhibit significant changes in the control group (Figs. 9A,B). However, KLA-induced activation resulted in reduced OCRs in PG(18:1)2-supplemented cells (Fig. 9B). For these cells, the OCRs from basal respiration, ATP production, and maximal respiration decreased by 37%, 17%, and 33%, respectively. In other words, PG(18:1)2 supplementation rescued the mitochondrial activity.

In PG(18:2)2-supplemented cells, KLA reduced the OCRs of the mitochondria in RAW264.7 cells (Fig. 9C); specifically, those from basal respiration, ATP production, and maximal respiration decreased by 27%, 13%, and 33%, respectively. After KLA activation, compared with PG(18:1)2-supplemented cells, PG(18:2)2-supplemented cells exhibited a slightly alleviated the mitochondrial activity, which is probably due to the original reduction in PG(18:2)2 supplementation control.

mRNA expression of CL metabolism-related genes.

To further investigate the gene regulations associated with CL and MLCL profile changes in response to KLA activation and PG supplementation, we analyzed the mRNA expression of CL-metabolism-related genes through reverse transcription quantitative real-time polymerase chain reaction (Fig. 10). Three representative genes related to inflammatory responses, namely Ptgs1, Ptgs2, and Alox5, were evaluated (Fig. 10A). PG(18:1)2 and PG(18:2)2 supplementation alone in RAW264.7 cells resulted in 23% and 45% reductions in the mRNA expression of Ptgs1, respectively; however, no apparent effects were observed on the mRNA expression of Ptgs2 and Alox5. In RAW264.7 cells treated with KLA, the mRNA expression of Ptgs1 and Alox5 decreased by 66% and 77%, respectively, but that of Ptgs2 increased significantly by 358 folds, indicating significant macrophage activation.

After PG supplementation, KLA-induced inflammation reduced drastically. KLA did not affect the mRNA expression of Ptgs1 and Alox5, even after the supplementation of either PG(18:1)2 or PG(18:2)2, compared with cells without PG supplementation. However, both PG(18:1)2 and PG(18:2)2 drastically reduced the KLA-induced mRNA expression of Ptgs2 by 27.5 folds.
The mRNA expression of CL synthesis-related genes did not exhibit significant changes after KLA treatment and PG supplementation (Fig. 10B). Acyl-CoA:lyso cardiolipin acyltransferase-1 (Alcat1) and Taz are crucial in mitochondrial CL remodeling (Fig. 10C). When RAW264.7 cells were treated with KLA, the mRNA expression of Alcat1 and Taz decreased by 36% and 28% relative to the control group; however, other treatments exerted no significant effects. Furthermore, we analyzed the mRNA expression of fatty acid desaturase 2 (Fads2), which is associated with fatty acid desaturation, which is an important step during fatty acid elongation. The mRNA expression of Fads2 decreased by 49% after KLA treatment, and decreased by 64% and 40% after PG(18:1) 2 and PG(18:2) 2 supplementation, respectively. Additionally, a 40% downregulation of Fads2 mRNA expression was observed in cells with KLA and PG(18:2) 2 supplementation compared with those with only PG(18:2) 2 supplementation. This phenomenon was not observed in cells with PG(18:1) 2 supplementation alone.

KLA treatment and PG supplementation did not significantly change the mRNA expression of CL hydrolysis-related genes (Fig. 10D). However, the mRNA expression of Pld decreased by 64% after KLA activation in PG(18:2) 2-supplemented cells, and Pla2g6 mRNA expression increased by 65% after KLA activation in PG(18:1) 2-supplemented cells.

Cytochrome c (Cycs), BH3-interacting domain death agonist (Bid), and phospholipid scramblase 3 (Plscr3) were the genes associated with apoptosis regulation (Fig. 10E). In RAW264.7 cells treated with KLA, the mRNA expression of Cycs and Bid decreased by 32% and 37%, respectively, but that of Plscr3 increased by 108%. PG supplementation alleviated the effects of KLA on the mRNA expression of Cycs and Bid; however, the mRNA expression of Plscr3 was not affected or was only slightly affected by PG supplementation.

Discussion

KLA triggered the activation of macrophage-like RAW264.7 cells and stimulated the activation of TLR4, which stimulates the activation of PLA2, COX-1, and COX-2 to produce prostaglandins and leukotrienes. We observed a drastic 358-fold increase in the mRNA expression of Ptgs2 genes after KLA activation. However, the mRNA expression of Ptgs1 and Alox5 decreased by 66% and 77%, respectively. Thus, KLA mainly stimulated Ptgs2, but not Ptgs1 and Alox5, to produce prostaglandins in RAW264.7 cells.

Upon macrophage activation, the total quantity of CLs and MLCLs per cell did not change; however, the species became highly saturated, most likely due to the 50% downregulation of Δ-6 desaturase mRNA expression. However, the enzymes related to CL synthesis and remodeling were either unaffected or slightly inhibited, and the changes in CL species were not attributed to the gene regulation of CL synthesis and remodeling. Furthermore, the degradation-related genes, sPLA2 and PLD, were not induced. The present results strongly indicate that macrophage activation inhibits the elongation of fatty acid.

The activated cells altered their CL profiles to become highly saturated CL species, which may prevent the oxidation of double bonds in activated macrophages; however, this process may also reduce mitochondrial activity. Notably, a mitochondrial activity analysis clearly demonstrated a reduction in the OCRs from basal respiration and ATP production, and particularly, a 67% reduction in the OCR from maximal respiration. In this KLA-induced activation process, the mitochondria lost more than half of its capability to provide energy to cells.
Studies have proposed that CLs can stabilize the ETC complexes and store the protons in the intermembrane space. In this study, the mRNA expression of Plscr3 was upregulated after KLA activation, which potentially flipped CLs to the outer membrane and reduced their ability to support the ETC complexes, resulting in the loss of mitochondrial activity.

**Figure 10.** KLA activation and PG supplementation change the gene expression level in RAW264.7 cells. RAW264.7 cells treated with KLA and/or PG(18:1) or PG(18:2) were collected. The expression levels of (A) eicosanoid synthesis: Ptgs1, Ptgs2, Alox5 (B) CL synthesis: Cds1, Pgs1, Crls (C) CL remodeling: Alcat1, Taz, Fads2 (D) CL catabolism: Pld, Pla2g6, Pnpla8 and (E) apoptosis: Cysc, Bid, Plscr3 related genes were quantitated by RT-qPCR. The data were triplicated and statically analyzed by Microsoft Excel t-Test (*p < 0.05, **p < 0.01, ***p < 0.001).
KLA-stimulated inflammation can significantly alter CL profiles. The energy production is likely to be highly regulated. We hypothesized that the changes in CL profiles during CL synthesis, remodeling, or degradation can inhibit or prevent excessive inflammation. RAW264.7 cells were supplemented with PG and CDP-DAG, which were the two reactants of CL synthesis. The incorporation of CDP-DAG into the mitochondrial membrane was not as effective as PG. To our surprise that PG supplementation caused the decrease of CL concentration, which is against our hypothesis that the increase of PG reactant will produce more CL product in the CL synthesis reaction. This indicates there are other factors involved to regulate CL synthesis. Previous research has been shown that PG is not only a reactants for CL synthesis, but may also act as a competitor to CL-binding proteins, which also stabilized the protein complexes that require CL binding to replace the necessity of CL in mitochondria. Therefore, excessive mitochondrial PG triggered the CL hydrolysis and caused the decreases of the CL and the increases of the MLCL concentration.

On the basis of the fatty acid compositions of CLs in cells, 18:1 and 18:2 were the two most common fatty acyl chains. PG(18:1) and PG(18:2) were selected to compare the saturation effects. The incorporation of both PG types was exceptionally efficient (Fig. 3), and provides excellent models to examine mitochondria activity and elucidate the regulatory mechanisms. Moreover, several different types of CL profiles were generated, particularly in the saturation of C72 and C74 groups. The two PG types also reduced the CL concentration and increased the MLCL concentration, resulting in a 60% reduction in the CL/MLCL ratio. The mitochondrial activities between PG(18:1),-supplemented and PG(18:2),-supplemented cells did not exhibit significant difference. Notably, PG supplementation did not affect the mRNA expression of CL metabolism-related genes, except to inhibit Δ6 desaturase. The mRNA expression of CL metabolism-related genes was mostly unaffected by PG supplementation; however, a slight downregulation of Ptgs1 mRNA expression was observed. Altogether, although PG incorporation significantly altered the mitochondrial phospholipid components, the cellular mitochondrial functions remained affected.

Evidence from the present study supports the idea that PG supplementation suppresses inflammation, particularly the 358-fold reduction in Ptgs2 mRNA expression after PG(18:1), and PG(18:2), supplementation, which was not observed in Ptgs1 or Alox5 mRNA expression. Although KLA activation of PG(18:1),-supplemented cells did not change the CL/MLCL ratio, the ratio was significantly reduced in PG(18:2),-supplemented cells. Because abnormal MLCL accumulation can trigger the aggregation of mitochondrial cristae in people with Barth syndrome, PG(18:1), was a more favorable PG type for medical purposes than PG(18:2). One study reported that the Taz gene defects associated with Barth syndrome can reduce the in vitro remodeling of PG(18:2) and CL(18:2), but not PG(18:1),. Furthermore, the highly unsaturated forms of CLs and MLCLs can undergo oxidation during KLA-induced inflammation. Therefore, macrophage activation significantly increases CL saturation. After PG supplementation, KLA-triggered desaturation effects were ineffective, probably because desaturation was nonessential in the inflammation-suppressed conditions. KLA-induced macrophage activation drastically reduced the mitochondrial activity; however, the effects of KLA were alleviated after supplementation with both PG types. In addition, Δ6 desaturase was inhibited after KLA addition in PG(18:2),-supplemented cells.

Materials and Methods

Materials. Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco (St. Louis, MO). Tetra-myristoyl cardiolipin standard CL(14:0),, phosphatidylglycerol standard PG(18:1),, PG(18:1), and CDP-DAG(18:1), standard were purchased from Avanti Polar Lipids (Alabaster, AL). 3-deoxy-d-manno-octulosonic acid-lipid A (Kdo2-Lipid A; KLA), (S)-Bromoenol lactone (S-Bel), (R)-Bromoenol lactone (R-Bel) were bought from Cayman (Ann Arbor, MI). Bio-Rad protein assay, iScript™ cDNA synthesis Kit and iQ™ SYBR® Green Supermix were purchased from Bio-Rad (Hercules, CA). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), oligomycin and FCCP were purchased from Sigma-Aldrich (St. Louis, MO). Rotenone was acquired from Merck EMD Millipore (Billerica, MA). Mitochondria isolation kit for cultured cells was purchased from Thermo Fisher Scientific, US.

Hydrolysis of CL by sPLA2. The 50 nmole CL(14:0), standard in chloroform was air-dried with N2 gas. The dried CL was resuspended in 498 μl of buffer (50 mM Tris–HCl, 5 mM CaCl2, pH 8) and sonicated for 10 times under the condition of 125 watt, 5 sec cycle, amplitude 80% to make CL vesicles. The hydrolysis reaction was initiated by adding 2 μl of purified sPLA2, and incubated at 40 °C water bath for 3 hours. After 3 hours of incubation, the reaction was stopped by adding 2 μl of methanol (MeOH). Fatty acids were extracted by Bligh-Dyer methods and subjected to mass spectrometry analysis.

Cell culture and KLA activation. Mouse leukaemic monocyte macrophage cell line (RAW264.7) was cultured in Dulbecco’s modified eagle medium with 10% fetal bovine serum, which was heat-inactivated for 30 minutes at 56 °C, 0.5% penicillin-streptomycin and 25 mM HEPES in 5% CO2 at 37°C. While cells were grown to 80% confluency in culture dishes, the cells were removed from dishes by treatment with 0.05% trypsin-EDTA solutions and washed with PBS before cell seeding. For activation, the adherent RAW264.7 cells were treated with 100 ng/ml of KLA for 24 hours.

PG and CDP-DAG Treatments. RAW264.7 cells were cultured in Dulbecco’s modified eagle medium with 10% heat-inactivated fetal bovine serum, 0.5% penicillin-streptomycin and 25 mM HEPES in 5% CO2 at 37°C. The collected 6 × 10^6 cells were transfected to a 6-cm culture dish and treated with 50 μM of CDP-DAG or PG(18:1), or PG(18:2), twice at 0 and 12 hours at 37°C before harvest at 48 hours. In the KLA activation experiments, 100 ng/ml of KLA was added at 24 hours and harvested at 48 hours. In the multiple supplementation treatment, 50 μM of PG(18:1), were added four times to cells at 0, 12, 24 and 36 hours. The cells were then harvested at
48 hours, washed with PBS and stored in −20 °C until lipid extraction. CDP-DAG or PG(18:1), or PG(18:2), were dissolved in ethanol. The final concentration of ethanol in medium was 0.16%.

**Phospholipid Analysis.** The 2 × 10⁷ RAW264.7 cells treated with PG(18:1), were harvested for mitochondria isolation following the protocol of mitochondria isolation kit (Thermo scientific, US). In brief, 800 μL of Mitochondria Isolation Reagent A, was added to cells. The samples were incubated ice for 2 minutes. Then, add 10 μL of Mitochondria Isolation Reagent B, and incubate the samples on ice for 5 minutes. After added 800 μL of Mitochondria Isolation Reagent C, the samples were gently mixed and centrifuge at 700 × g for 10 minutes at 4 °C. The samples were centrifuged at 12,000 × g for 15 minutes at 4 °C to collect the isolated mitochondria. The ingredients of the Reagent A, B and C are not disclosed by Thermo scientific. The isolated mitochondria were added 1 ml of MeOH for sonication for 60 sec. The phospholipids were extracted by Bligh-Dyer’s method. The extracted lipids were N₂ dried and then re-suspended in 200 μL of ACN(acetonitrile)/IPA(isopropanol)/DDW(Distilled and deionized water) (65/30/5) for LC-MS/MS analysis.

**Lipid Extraction.** The total lipid in the collected cell was extracted according to the Bligh-Dyer’s method as our previous experiments 48. The internal standard, 0.2 nmole tetramyristoyl cardiolipin CL(14:0)₄, was added to the cell pallets in 2 ml MeOH. After 3 times of pulse sonication at the condition of 125 watt, 20 sec, amplitude 80% on ice, 1 mL of dichloromethane was mixed with samples, which were further vortexed for 10 min. Then, 1 ml of dichloromethane and 1 ml of distilled deionized water were added to samples and further vortexed for 10 min. The lower phase in the glass test tube was collected by centrifugation at 2000 rpm for 5 min and the lipid sample was stored at −20 °C.

**Mass Spectrometry Analysis.** The extracted total lipid was dried under nitrogen gas and immediately re-dissolved with acetonitrile/2-propanol/H₂O (65:30:5). The samples were capped and stored in −20 °C to prevent evaporation until LC/MS Ion-Trap analysis (Bruker Corporation). Reverse phase HPLC contained solution A: ACN:H₂O (60:40), 10 mM ammonium formate, 0.1% formic acid and solution B: IPA:ACN (90:10), 10 mM ammonium formate, 0.1% formic acid for the elution gradient from 60% solution A/40% solution B to 100% solution B in 25 min and maintained 100% solution B until 45 min. The elution was in an Acclaim RSLC 120 C18 2.1 mm × 100 mm 2.2 μm column (Thermo) at a flow rate of 0.2 mL/min at 55 °C. Data were further analyzed by Bruker DataAnalysis (ver.4.1). The extract ion current (XIC) of each cardiolipin species was quantitated by their area ratio to internal standard. The total CL is the ratio of XIC of each cardiolipin species to total XIC. Standard deviations were calculated by the STDEV function in Microsoft Excel for the error bars of the histograms and t-tests are applied to all triplicated data

**MTT Assay.** RAW246.7 cells were cultured in DMEM with 10% heat inactivated fetal bovine serum in 5% CO₂ at 37 °C. The 1 × 10⁴ cells were transferred to a 24-well culture plate and treated with 10 μM, 25 μM, 50 μM, 100 μM, 250 μM and 500 μM PG(18:1), for 24 hours at 37 °C, washed with PBS, and added medium containing 0.5 mg/ml MTT(3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide). After 4 hours of incubation at 37°C, MTT turned into purple formazan crystal. The medium was replaced with 200 μL of DMSO for 5 min. The absorbance of the dissolved cells in DMSO was measured at the wavelength of 550 nm.

**Seahorse Mitochondrial Assay.** A total of 5 × 10⁴ RAW264.7 cells were seeded into each well of XF-24 cell culture microplate (Seahorse Bioscience) and allowed to adhere. The cells were then supplemented with 50 μM PG(18:1), or PG(18:2), twice at 0 and 12 hour. At 24 hour, 100 ng/ml KLA was added and the cells were incubated for another 24 hours. The media was replaced with DMEM pH 7.4 for 1 hour at 37 °C. The cell oxygen consumption rate (OCR) was analyzed by Seahorse XFe Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA). The optimized concentrations of the mitochondrial inhibitors in the experiments were 10 μM oligomycin, 1 μM FCCP and 5 μM rotenone. After seahorse mitochondrial assay, the protein concentration in each well of the XF24 cell culture microplate was measured by Bradford protein assay. The microplate was added 50 μL of 0.1% triton in PBS to each well and placed on ice for 5 min, and then 450 μL of DDW was added to each sample. The Bradford assay was started by mixing 10 μL of the prepared sample with 190 μL of 1X solution of Bradford protein-binding assay (Bio-Rad) in a 96-well plate. The absorbance at wavelength 595 nm of the plate was measured by SpectraMax M Series Multi-Mode Microplate Readers (Molecular Devices). The protein concentration was calculated based on the standard curve of BSA.

**mRNA Extraction and Reverse Transcription.** RAW264.7 cells were washed with cold PBS, added 1 ml of TRIZOL reagent and then placed on ice for 5 min. The cells were transferred to a 1.5 ml eppendorf tube and added 200 μL of chloroform. The upper phase in the tube was collected after centrifugation at 12000 rpm for 15 min at 4 °C. Equal 500 μl of supernatant and isopropanol were mixed gently and kept at −20 °C for 20 min. The sample was then placed at room temperature for 10 min and collected the precipitate by centrifugation at 12000 rpm for 15 min at 4 °C. The precipitate was washed with 500 μL of ethanol and centrifuged at 9000 rpm for 5 min at 4 °C. After removing the supernatant, the sample was added 20 μL of DEPC water and heated to 50 °C for 5 min to restore the mRNA sample. The cDNA synthesis Kit from Bio-Rad was utilized for the mRNA reverse transcription. Briefly, 1 μg mRNA was mixed with 4 μl qscript reaction mix and 1 μl qscript reverse transcriptase, and then DEPC treated water was added to 20 μL of total volume. The sample was kept at room temperature for 5 min, and then heated to 42 °C for 30 min and 85°C for 5 min. After DNA quantitation, the sample was stored at −20 °C.
Real-time quantitative PCR. The quantitative PCR mix contains 50 ng of cDNA, 10 pmole of forward primer, 10 pmole of reverse primer and 10 μl of iQ™ SYBR® Green Supermix (Bio-Rad) in a total 20 μl volume. The sequences of the primers are provided in Supplemental Fig. S4. The samples were analyzed by MiniOpticon Real-Time PCR System (Bio-Rad, Hercules, CA). The cycling conditions were 180 sec at 95 °C for initial polymerase activation and 40 cycles of 15 sec at 95 °C and 90 sec at 60 °C. For melting curve measurement, the temperature was increased 0.1 °C per second.

References
1. Barton, G. M. A calculated response: control of inflammation by the innate immune system. The Journal of clinical investigation 118, 413–420 (2008).
2. Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nature immunology 6, 1191–1197 (2005).
3. Majno, G. & Joris, I. Cells, tissues, and disease: principles of general pathology. 2nd edn, (Oxford University Press, 2004).
4. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428–435 (2008).
5. Gilca, M., Stoian, I., Atanasiu, V. & Virgolici, B. The oxidative hypothesis of senescence. Journal of postgraduate medicine 53, 207–213 (2007).
6. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).
7. Mills, E. L. et al. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. Cell 167, 457–470 e413 (2016).
8. Naik, E. & Dixit, V. M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. The Journal of experimental medicine 208, 417–420 (2011).
9. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature immunology 12, 222–230 (2011).
10. Tuominen, A. Phosphatidylglycerol in lung surfactant. III. Possible modifier of surfactant function. Biochimica et biophysica acta 108, 6264–6269 (2011).
11. Wang, Y., Wang, G. Z., Rabinovitch, P. S. & Tabas, I. Macrophage mitochondrial oxidative stress promotes atherosclerosis and macrophage foam cell formation. Circulation research 114, 421–433 (2014).
12. Benson, A. A. & Maruo, B. Plant phospholipids. I. Identification of the phosphatidyl glycerols. 1958.
13. Belikova, N. A. Peroxidase activity and structural transitions of cytochrome c bound to cardiolipin-containing membranes. The Biochemical journal 407, 179–187 (2007).
14. Belikova, N. A. et al. Peroxidase activity and structural transitions of cytochrome c bound to cardiolipin-containing membranes. Biochemistry 45, 4998–5009 (2006).
15. Lesniewski, E. J., Slabe, T. J., Stoll, M. S., Minkler, P. E. & Hoppel, C. L. Myocardial ischemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria. Am J Physiol Heart Circ Physiol 280, H2770–2778 (2001).
16. Paradies, G., Petrosillo, G. & Ruggiero, F. M. Cardiolipin-dependent decrease of cytochrome c oxidase activity in heart mitochondria from hypothyroid rats. Biochimica et biophysica acta 1319, 5–8 (1997).
17. Kielish, M. A., Han, X., Cheng, H., Chuang, J. H. & Seyfried, T. N. Cardiolipin and electron transport chain abnormalities in mouse brain tumour mitochondria: lipidomic evidence supporting the Warburg theory of cancer. Journal of lipid research 49, 2545–2556 (2008).
18. Abe, M., Nibayashi, R., Koubori, S., Motiyama, I. & Miyoshi, H. Molecular mechanisms for the induction of peroxidase activity of the cytochrome c-cardiolipin complex. Biochemistry 50, 8383–8391 (2011).
19. Kim, T. H. et al. Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome c release. Mol Biol Cell 15, 3061–3072 (2004).
20. Paradies, G. et al. Peroxidase activity from hypothyroid rats. Biochimica et biophysica acta 1319, 5–8 (1997).
21. Schlame, M., Ren, M., Xu, Y., Greenberg, M. L. & Haller, I. Molecular symmetry in mitochondrial cardiolipins. Chemistry and physics of lipids 138, 38–49 (2005).
22. Ting, H. C., Chao, Y. J. & Hsu, Y. H. Cytochrome c release. Mol Biol Cell 15, 3061–3072 (2004).
23. Belikova, N. A. et al. Peroxidase activity and structural transitions of cytochrome c bound to cardiolipin-containing membranes. Biochemistry 45, 4998–5009 (2006).
24. Xu, Y., Malhotra, A., Ren, M. & Schlame, M. The enzymatic function of tafazzin. The Journal of biological chemistry 281, 32921–32924 (2006).
25. Ting, H. C., Chao, Y. J. & Hsu, Y. H. Polynsaturated fatty acids incorporation into cardiolipin in H9c2 cardiac myoblast. J Nutr Biochem 26, 769–775 (2015).
26. Chao, Y. J., Chang, W. H., Ting, H. C., Chao, W. T. & Hsu, Y. H. Cell cycle arrest and cell survival induce reverse trends of cardiolipin remodeling. PloS one 9, e13680 (2014).
27. Barth, P. G. et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci 62, 327–355 (1983).
28. Hsu, Y. H., Dumla, D. S., Cao, J. & Dennis, E. A. Assessing phospholipase A2 activity toward cardiolipin by mass spectrometry. PloS one 8, e59267 (2013).
29. Benson, A. A. & Maruo, B. Plant phospholipids. I. Identification of the phosphatidyl glycerols. 1958.
30. Stanacev, N. Z., Chang, Y. Y. & Kennedy, E. P. Biosynthesis of cardiolipin in Escherichia coli. The Journal of biological chemistry 242, 3018–3019 (1967).
31. King, R. J. & MacBeth, M. C. Interaction of the lipid and protein components of pulmonary surfactant. Role of phosphatidylglycerol and calcium. Biochimica et biophysica acta 647, 159–168 (1981).
32. Numata, M., Kandasamy, P. & Voelker, D. R. Anionic pulmonary surfactant lipid regulation of innate immunity. Expert review of respiratory medicine 6, 243–246 (2012).
33. Ballman, M. & Gluck, L. Phosphatidylglycerol in lung surfactant. III. Possible modifier of surfactant function. Journal of lipid research 17, 257–262 (1976).
34. Kulakova, K. et al. Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2. The Journal of biological chemistry 284, 25488–25500 (2009).
35. Kandasamy, P. et al. Pulmonary surfactant phosphatidylglycerol inhibits Mycoplasma pneumoniae-stimulated eicosanoid production from human and mouse macrophages. The Journal of biological chemistry 286, 7841–7853 (2011).
36. Andreyev, A. Y. et al. Subcellular organelle lipidomics in TLR-4-activated macrophages. Journal of lipid research 51, 2785–2797 (2010).
37. Numata, M., Chu, H. W., Dakhama, A. & Voelker, D. R. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 320–325 (2010).

38. Gomez, B. Jr & Robinson, N. C. Phospholipase digestion of bound cardiolipin reversibly inactivates bovine cytochrome bc1. *Biochemistry* **38**, 9031–9038 (1999).

39. Eble, K. S., Coleman, W. B., Hantgan, R. R. & Cunningham, C. C. Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy. *The Journal of biological chemistry* **265**, 19434–19440 (1990).

40. Haines, T. H. & Dencher, N. A. Cardiolipin: a proton trap for oxidative phosphorylation. *FEBS Lett* **528**, 35–39 (2002).

41. Renner, L. D. & Weibel, D. B. MinD and MinE interact with anionic phospholipids and regulate division plane formation in Escherichia coli. *The Journal of biological chemistry* **287**, 38835–38844 (2012).

42. Gold, V. A. *et al.* The action of cardiolipin on the bacterial translocon. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 10044–10049 (2010).

43. Arias-Cartin, R. *et al.* Cardiolipin-based respiratory complex activation in bacteria. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 7781–7786 (2011).

44. Makise, M., Mima, S., Katsu, T., Tsuchiya, T. & Mizushima, T. Acidic phospholipids inhibit the DNA-binding activity of DNAJ protein, the initiator of chromosomal DNA replication in Escherichia coli. *Molecular microbiology* **46**, 245–256 (2002).

45. Powl, A. M., East, J. M. & Lee, A. G. Lipid-protein interactions studied by introduction of a tryptophan residue: the mechanosensitive channel MscL. *Biochemistry* **42**, 14306–14317 (2003).

46. Houtkooper, R. H. *et al.* Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. *Anal Biochem* **387**, 230–237 (2009).

47. Vreken, P. *et al.* Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. *Biochem Biophys Res Commun* **279**, 378–382 (2000).

48. Chao, Y. J., Chan, J. F. & Hsu, Y. H. Chemotherapy Drug Induced Discoordination of Mitochondrial Life Cycle Detected by Cardiolipin Fluctuation. *PloS one* **11**, e0162457 (2016).

**Acknowledgements**

This work was supported by Ministry of Science and Technology, Taiwan. (MOST 105-2113-M-029-009 and MOST 106-2923-M-029-001-MY3) and National Health Research Institutes, Taiwan (NHRI-EX105-10236SC) to YHH.

**Author Contributions**

W.W.C. and W.H.C. did the experiments, analyzed the data and prepared the figures. Y.J.C. prepared the figures and wrote the manuscript. J.F.C. revised the manuscript and all figures. Y.H.H. designed the experiments, analyzed the data, wrote the manuscript and prepared the figures.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23190-z.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018